002901.SZ
Double Medical Technology, Inc.
SZSE · Healthcare · C 制造业 · CN
CNY 41.03
+1.28%Oct 25, 2026, 07:44 UTC
Da Bo Medical reported third-quarter 2026 revenue of 737 million yuan, up 10.62% year over year, and net profit attributable to shareholders of 118 million yuan, down 34.59%.
Source:Oct 12, 2026, 08:45 UTC
Da Bo Medical approved an adjustment to its share repurchase plan, raising the total funding range to RMB 140 million–280 million while keeping the price cap at RMB 49.41 per share; the shares are intended for an equity incentive plan.
Source:Aug 1, 2026, 00:33 UTC
On August 1, 2026, 47 Chinese A-share companies disclosed various stages of stock buyback progress, including shareholder proposals, initial plans, implementation updates, and completed buybacks.
Source: